Instytut Podstawowych Problemów Techniki
Polskiej Akademii Nauk

Partnerzy

Beata Franczyk

Medical University of Lodz (PL)


Ostatnie publikacje
1.  Gluba-Brzózka A., Franczyk B., Olszewski R., Rysz J., The influence of inflammation on anemia in CKD patients, International Journal of Molecular Sciences, ISSN: 1422-0067, DOI: 10.3390/ijms21030725, Vol.21, No.3, pp.725-1-25, 2020

Streszczenie:
Anemia is frequently observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient's life. It also enhances morbidity and mortality and hastens the KD progression rate. Patients with CKD frequently suffer from a chronic inflammatory state which is related to a vast range of underlying factors. The results of studies have demonstrated that persistent inflammation may contribute to the variability in Hb levels and hyporesponsiveness to erythropoietin stimulating agents (ESA), which are frequently observed in CKD patients. The understanding of the impact of inflammatory cytokines on erythropoietin production and hepcidin synthesis will enable one to unravel the net of interactions of multiple factors involved in the pathogenesis of the anemia of chronic disease. It seems that anti-cytokine and anti-oxidative treatment strategies may be the future of pharmacological interventions aiming at the treatment of inflammation-associated hyporesponsiveness to ESA. The discovery of new therapeutic approaches towards the treatment of anemia in CKD patients has become highly awaited. The treatment of anemia with erythropoietin (EPO) was associated with great benefits for some patients but not all.

Słowa kluczowe:
inflammation, chronic kidney disease, anemia, anemia of inflammation, ESA hyporesponsiveness

Afiliacje autorów:
Gluba-Brzózka A. - WAM Teaching Hospital (PL)
Franczyk B. - Medical University of Lodz (PL)
Olszewski R. - IPPT PAN
Rysz J. - Medical University of Lodz (PL)
140p.
2.  Rysz J., Franczyk B., Ławiński J., Olszewski R., Gluba-Brzózka A., The role of metabolic factors in renal cancers, International Journal of Molecular Sciences, ISSN: 1422-0067, DOI: 10.3390/ijms21197246, Vol.21, No.19, pp.7246-1-20, 2020

Streszczenie:
Anincreasing number of evidence indicates that metabolic factorsmayplay an important role in the evelopment and progression of certain types of cancers, including renal cell carcinoma (RCC). This tumour is the most common kidney cancer which accounts for approximately 3–5% of malignant tumours in adults. Numerous studies indicated that concomitant diseases, including diabetes mellitus (DM) and hypertension, as well as obesity, insulin resistance, and lipid disorders, may also influence the prognosis and cancer-specific overall survival. However, the results of studies concerning the impact of metabolic factors on RCC are controversial. It appears that obesity increases the risk of RCC development; however, it may be a favourable factor in terms of prognosis. Obesity is closely related to insulin resistance and the development of diabetes mellitus type 2 (DM2T) since the adipocytes in visceral tissue secrete substances responsible for insulin resistance, e.g., free fatty acids. Interactions between insulin and insulin-like growth factor (IGF) system appear to be of key importance in the development and progression of RCC; however, the exact role of insulin and IGFs in RCC pathophysiology remains elusive. Studies indicated that diabetes increased the risk of RCC, but it might not alter cancer-related survival. The risk associated with a lipid profile is most mysterious, as numerous studies provided conflicting results. Even though large studies unravelling pathomechanisms involved in cancer growth are required to finally establish the impact of metabolic factors on the development, progression, and prognosis of renal cancers, it seems that the monitoring of health conditions, such as diabetes, low body mass index (BMI), and lipid disorders is of high importance in clear-cell RCC.

Słowa kluczowe:
renal cell carcinoma, obesity, insulin resistance, diabetes mellitus, lipid disorders

Afiliacje autorów:
Rysz J. - Medical University of Lodz (PL)
Franczyk B. - Medical University of Lodz (PL)
Ławiński J. - inna afiliacja
Olszewski R. - IPPT PAN
Gluba-Brzózka A. - WAM Teaching Hospital (PL)
140p.
3.  Gluba-Brzózka A., Franczyk B., Ciałkowska-Rysz A., Olszewski R., Rysz J., Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients, Nutrients, ISSN: 2072-6643, DOI: 10.3390/nu10060709, Vol.10, No.709, pp.1-12, 2018

Streszczenie:
In patients suffering from chronic kidney disease (CKD), the prevalence of cardiovascular disease is much more common than in the general population. The role of vitamin D deficiency had been underestimated until a significant association was found between vitamin D therapy and survival benefit in haemodialysis patients. Vitamin D deficiency is present even in the early stages of chronic kidney disease. The results of experimental studies have revealed the relationship between vitamin D deficiency and impairment of cardiac contractile function, higher cardiac mass and increased myocardial collagen content. Experimental models propose that intermediate end points for the relationship between vitamin D deficiency and higher risk of cardiovascular disease comprise diminished left ventricular hypertrophy (LVH), enhanced left ventricular diastolic function, anddecreasedfrequencyofheartfailure. Multipleobservationalstudieshavedemonstrated an association between the use of active vitamin D therapy in patients on dialysis and with CKD and improved survival. However, there are also many studies indicating important adverse effects of such treatment. Therefore, large randomized trials are required to analyze whether supplementation of vitamin D may affect outcomes and whether it is safe to be used in CKD patient

Słowa kluczowe:
vitamin D, chronic kidney disease, cardiovascular disease, mortality, vitamin D analogues, treatment

Afiliacje autorów:
Gluba-Brzózka A. - WAM Teaching Hospital (PL)
Franczyk B. - Medical University of Lodz (PL)
Ciałkowska-Rysz A. - Medical University of Lodz (PL)
Olszewski R. - IPPT PAN
Rysz J. - Medical University of Lodz (PL)
35p.
4.  Gluba-Brzózka A., Franczyk B., Olszewski R., Banach M., Rysz J., Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases, International Journal of Molecular Sciences, ISSN: 1422-0067, DOI: 10.3390/ijms18061248, Vol.18, pp.1248-1-20, 2017

Streszczenie:
The prevalence of renal diseases is rising and reaching 5–15% of the adult population. Renal damage is associated with disturbances of body homeostasis and the loss of equilibrium between exogenous and endogenous elements including drugs and metabolites. Studies indicate that renal diseases are influenced not only by environmental but also by genetic factors. In some cases the disease is caused by mutation in a single gene and at that time severity depends on the presence of one or two utated alleles. In other cases, renal disease is associated with the presence of alteration within a gene or genes, but environmental factors are also necessary for the development of disease. Therefore, it seems that the analysis of genetic aspects should be a natural component of clinical and xperimental studies. The goal of personalized medicine is to determine the right drug,for the right patient,at the right time. Whole-genome examinations may help to change the approach to the disease and the patient resulting in the creation of“personalized medicine”with new diagnostic and treatment strategies designed on the basis of genetic background of each individual. The identification of high-risk patients in pharmacogenomics analyses will help to avoid many unwarranted side effects while optimizing treatment efficacy for individual patients. Personalized therapies for kidney diseases are still at the preliminary stage mainly due to high costs of such analyses and the complex nature of human genome. This review will focus on several areas of interest: renal disease pathogenesis, diagnosis, treatment, rate of progression and the prediction ofprognosis.

Słowa kluczowe:
renal diseases, personalized medicine, treatment, diagnosis, biomarkers

Afiliacje autorów:
Gluba-Brzózka A. - WAM Teaching Hospital (PL)
Franczyk B. - Medical University of Lodz (PL)
Olszewski R. - IPPT PAN
Banach M. - Medical University of Lodz (PL)
Rysz J. - Medical University of Lodz (PL)
30p.

Kategoria A Plus

IPPT PAN

logo ippt            ul. Pawińskiego 5B, 02-106 Warszawa
  +48 22 826 12 81 (centrala)
  +48 22 826 98 15
 

Znajdź nas

mapka
© Instytut Podstawowych Problemów Techniki Polskiej Akademii Nauk 2021